Listing Regulation – iZafe Group

iZafe Group announces that CFO Ida Almgren will be stepping down

iZafe Group AB ("iZafe Group") today announces that Ida Almgren has decided to step down as Chief Financial Officer to explore new career opportunities.

During the transition period, Ida will actively assist iZafe Group to ensure a smooth transition, while a search process for a new CFO commences. Ida's last day of work will be June 18.

iZafe is deeply committed to a stable transition and to continuously delivering value to our shareholders and stakeholders. We are fully focused on executing our long-term strategy and realizing our business plans with precision and determination.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group announces that CFO Ida Almgren will be stepping down

Ida Almgren2

iZafe Group Q2 Interim Report, April-June 2023

iZafe Group AB (publ.) presents today, August 25, its report for the second quarter.

Financial Performance in Summary

Net sales for the quarter amounted to SEK 403 (84) thousand, a growth of 380% compared to the corresponding quarter last year. The increase in turnover can partly be attributed to organic growth, partly to growth through acquisition, when Pilloxa was acquired in December 2022. Excluding the turnover from the acquired company, the growth amounted to 198%. The quarter’s turnover consists of income attributable to the sale of the digital pharmaceutical robot Dosell and the sale of the medical device Pilloxa. Pilloxa AB was acquired on 28 November 2022 and is therefore not included in the quarter’s turnover for the previous year.
Operating profit for the quarter amounted to SEK -5,097 (-5,184) thousand.
Profit after financial items for the quarter amounted to -5,136 (-5,233) TSEK.
Cash flow for the period amounted to SEK -3,496 (-7,155) thousand.
Earnings per share for the quarter before / after dilution amounted to SEK 0.0 (-0.1).
Equity per share amounted to SEK 0.2 (0.4) at the end of the period.
The equity ratio at the end of the period amounted to 82.4 (81.8) percent.

Significant events during the quarter

iZafe has signed a cooperation agreement with Spanish Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi’s minimum commitment over a four-year period is worth at least SEK 12 million.
iZafe has signed a cooperation agreement with MDM Pulse for the right to sell and market the medicine robot Dosell in Portugal. MDM Pulse’s minimum commitment over a five-year period amounts to SEK 12.2 million to subsequently generate a recurring license income of at least SEK 4.2 million annually.

Significant events after the end of the quarter

iZafe successfully completed all necessary technical integrations and adaptations to launch Dosell on the Dutch market. The company will now deliver 50 units for testing. After successful testing, the remaining 1,000 units will be delivered successively during the year.

Comments from CEO
I am pleased to share with you the latest progress and developments in our company during the past quarter. Despite an initially low turnover, our focus on the right strategies and measures has resulted in a positive increase in our turnover. This increase, although it may be modest, marks a turning point in the right direction. Together with our continuous effort to streamline and reduce costs, we now stand on a stable foundation.

I feel confident that the liquidity we obtained in March will be sufficient to bring us to a cash flow positive position. Our determination to optimize our finances and capital utilization has set us on this promising path forward. I would like to express my heartfelt thanks to you for your continued trust and investment in our company. Your faith in us has been a decisive factor in our success.

During the first half of the year, we communicated about several significant orders that lie ahead. Now our top priority is to ensure that the deliveries of these orders are carried out smoothly. One of our most challenging tasks is to deliver 1,000 units to the Netherlands before the end of this year. The first 50 units will be used to guarantee a seamless customer experience with our innovative solution, uniquely tailored to the needs of the Dutch market. The setup is a result of our joint work with investments from both the partner, Dutch IVE Ventures, and us, where IVE Ventures invested in a comprehensive system where Dosell has a key function. Tests are currently underway and are expected to be completed shortly. When potentially needed fine adjustments in the customized system solution are in place after feedback from the tests, we will gradually deliver the remaining units according to plan.

We also see positive progress in Spain, where plans are progressing as previously communicated. During Q2, an agreement worth minimum SEK 12 million over four years was secured, including 1,800 Dosell units. The Spanish partner Ti-Medi delivers today solutions to facilitate correct medication to over 650 pharmacies in Spain and Portugal. During the autumn, we are working intensively to adapt Dosell and the customer journey for the Spanish market, which will hopefully lead to an extensive launch during the first quarter of 2024.

Also in Italy we have worked further to develop our collaborations. Our partner has been working for some time to achieve a wider acceptance of sachets in the Italian market. They are currently conducting a funding round to secure the necessary capital to accelerate sales of our pharmaceutical robots along with their innovative sachets on a larger scale.

In the UK, we are on the verge of completing our first pilot, which is a milestone for us. This marks the start of gradually increasing sales that are expected to pick up from the turn of the year. The UK is a market with huge potential, and we foresee steady growth as the market matures.

In our home region, the Nordics, our work with municipalities in Sweden and Norway has yielded results. The decision to expand the use of Dosell within these municipalities is a clear indication that our product is appreciated for its simplicity, functionality and its ability to relieve care by ensuring correct medication at the right time. I am optimistic that we will see increasing demand also here in the Nordics during the autumn, and a positive trend that is expected to grow significantly in the coming year.

Our latest acquisition, Pilloxa, has added additional value to our portfolio. Our focus now is on ensuring customer satisfaction through smooth deliveries and maximizing the potential of our new customers. Going forward, we aim to merge our concepts into a world-unique concept that can help the patient at all stages; regardless of how they manage their medication, but right now our primary focus is on ensuring that Dosell deliveries to our partners around Europe.

In summary, we are stronger and more well prepared than ever. With a stable liquidity that is expected to bring us to a cash flow positive position, together with the majority of orders received and a growing demand, we are enthusiastically looking forward to the upcoming autumn. I am convinced that, together with my amazing team, we will be able to achieve outstanding results.

Again, many thanks for your invaluable trust as a shareholder.

Anders Segerström
CEO, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution and the connected dose bag Pilloxa. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Interim Report Q2 2023

Intervju Q2 2023 iZafe Group

Omslagsbild Q2 2023

iZafe Group AB gets a new international strategic shareholder

iZafe Group AB ("iZafe Group" or the “Company”) hereby announces that that the Spanish company Ti-Medi has acquired approximately five percent of the shares in the Company, which makes Ti-Medi one of iZafe Group's largest shareholders. Ti-Medi has in total acquired 12,529,309 shares at the price of SEK 0.29 per share through a block deal brokered by Mangold Fondkommission.

Ti-Medi is a global company active in the manufacturing and distribution of technical solutions for compliance in pharmaceutical management. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.
For more information, see Ti-Medi's website, www.ti-medi.com/en.

"Our assessment is that the demand for iZafe Group's products and services will increase in the markets where we operate. We have long been looking for a company that develops and offers its customers precisely these types of services. Therefore, we have decided to invest in iZafe Group and we also hope to be able to find a good collaboration in the future to bring iZafe's products and services into Ti-Medi's product range in order to be able to offer these to our customers," says Marc Tarruell Tibau, co-founder of Ti-Medi

"The company has now gained a new strong and long-term owner that contributes with expertise and a global network. We view this very positively and interpret the investment as proof that iZafe Group's product and operations have support among knowledgeable market colleagues. We look forward to sharing the knowledge that Ti-Medi possesses about distribution in Southern Europe and initiating discussions about a future collaboration", says Anders Segerström, CEO of iZafe Group AB

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe Group AB gets a new international strategic shareholder

The last day of trading in the warrants of series TO13B in iZafe Group AB is today, March 6, 2023

Today, March 6, 2023, is the last day of trading with the warrants of series TO13B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO13B runs up until March 8, 2023. Each warrant of series TO13B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO13B is SEK 0.20 per share of series B.

If all the warrants of series TO13B are exercised, the Company will receive approximately SEK 23.7 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than March 8, 2023. Alternatively, the holder may sell the warrants, no later than today, March 6, 2023. Please be aware that certain nominees may close their subscriptions earlier than March 8, 2023. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

The last day of trading in the warrants of series TO13B in iZafe Group AB is today, March 6, 2023

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

In November 2022 iZafe Group AB ("iZafe" or the "Company") acquired Pilloxa AB and, in connection with the acquisition, carried out a directed issue of units consisting of shares of series B and warrants of series TO13B. To compensate existing shareholders for the dilution from the directed issue of units, and with the purpose of capitalizing iZafe in a favorable way, the Company issued warrants of series TO13B free of charge to all shareholders. A total of 118,556,833 warrants of series TO13B were issued. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price has been set to SEK 0.20 per share of series B. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023.

Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO13B shall correspond to 70 percent of the
volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the measurement period from and including February 9, 2023, up to and including February 22, 2023. However, not lower than the quota value for the Company's share, corresponding to SEK 0.20, and not higher than SEK 0.30 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.21. Thus, the subscription price is determined to SEK 0.20. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023. Complete terms and conditions for the warrants of series TO13B are available on the Company's website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Last day for trading warrants of series TO13B: March 6, 2023.

About Us

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

iZafe has been granted a new patent for safer medication handling at home

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and pre-packaged medication dose based on a patient-specific parameter," applies to the company's technology for medical and digital security solutions to create safer medication management in the home.

"This patent gives us additional protection in Sweden for medication handling at home. After the acquisition of Pilloxa, we are able to offer solutions for safe medication for the entire patient journey, which in practice means the following steps:
• Pill jars or other loose medicine in syringes, tablets or liquid form. Where, with the help of our app, we remind, show statistics and can send alarms.
• Sorting in "dosett" where we offer a smart connected version that, with the help of our app, helps with sorting, reminders, alarms and statistics.
• Medication in sachets where, with the help of Dosell, we automate the entire process in the medication.
With this patent, we can also create a unique solution for safer medication handling in the home and addressing a significent and increasing demand" says Anders Segerström, CEO of iZafe Group.

About Us

iZafe has been granted a new patent for safer medication handling at home

The medication robot Dosell is being implemented in two new municipalities

iZafe Group (publ.) hereby announces that the partner Careium Sweden AB is now starting the implementation of Dosell in two more municipalities in Sweden.

The municipalities, which together have approximately 13,500 residents aged 65 and over, initially start with 10 Dosells and then gradually increase the number.

Lack of adherence to medication is a major societal problem, which requires large resources to deal with. Dosell solves medication management in an efficient way and thus frees up the staff's time for care.

"We look forward to continuing the implementation of Dosell in more municipalities in the future and thereby working for greater independence for care recipients," says Martin Puumalainen Director Nordics and International for Careium AB

About Careium
Careium is one of the leading players in welfare technology in Europe and around 400,000 people use their services. The vast majority of these are connected to one of the company's four alarm centers in Sweden, Norway and Great Britain. The alarm centers receive more than 25,000 alarms a day. Read more at careium.com

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.com

About Us

The medication robot Dosell is being implemented in two new municipalities

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment of warrants of series TO13B has been set to December 23, 2022. The exercise period to subscribe for new shares with the support of warrants of series TO13B will be from and including February 23, 2023, to and including March 8, 2023. The first day of trading in the warrants of series TO13B on Nasdaq First North Growth Market will be on December 28, 2022.

As announced by press release on November 28, 2022, iZafe has completed a directed issue of shares and warrants of series TO13B (the “Directed Issue”). In order to give existing shareholders in the Company the opportunity to compensate for the dilution the Directed Issue entails, the Board of Directors of iZafe has also decided to issue warrants of series TO13B (same series as in the Directed Issue) to the Company, which then are allotted free of charge to the shareholders in the Company.

The record date to receive warrants of series TO13B has been set to December 23, 2022. Therefore, the last day of trading in the Company’s share including the right to receive warrants is December 21, 2022, and the first day of trading in the Company’s share excluding the right to receive warrants is December 22, 2022.

The Company’s existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date.

Terms and information regarding warrants of series TO13B

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent of the numbers of shares and approximately 42.69 percent of the votes.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the warrants of series TO13B.

About Us

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe Group AB (publ) hereby announces that the company has entered into an agreement with Mangold regarding the service as Certified Adviser.

Mangold will take over as Certified Adviser (CA) on 1 April 2023. Until then, FNCA will continue to act as Certified Adviser for the company.

About Us

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers.

“iZafe and the medicine robot Dosell are the only products on the market that can handle the dose bags that we deliver to our customers in outpatient and inpatient care. We are happy to develop the collaboration with iZafe, which is completely in line with our business concept of offering technical solutions to customers in public and private healthcare”, says John Patrick Berlips, licensed physician and founder of ApoEx.

ApoEx supplies dose bags to 3,500 patients and hospitals in several of the country's regions. In Stockholm, the company produces the sachets that, among others, Aleris uses in its healthcare deliveries.

“ApoEx offers smart comprehensive solutions of goods and services for both private and public healthcare and is therefore the right partner for us. As iZafe is currently in an expansive phase, our strategic partnerships are absolutely crucial for us. With these collaborations, we can more effectively develop successful solutions together”, says Anders Segerström, CEO of iZafe.

About ApoEx
ApoEx was founded in 2010 with the aim of simplifying and improving care. We have developed most solutions in close dialogue with our customers and the business is characterized by customer-driven innovation and the attitude that nothing is impossible. Over the years, thousands of healthcare companies in the private and public sector have chosen ApoEx as their strategic partner for the supply of medicines and consumables.

About Us

iZafe begins collaboration with ApoEx for enhanced patient safety